Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
Japanese Cabinet ministers approved a bill on the legal regulation of clinical research on May 13, sending it to the Diet for its deliberations in the current session, which will run through June 1. The bill, if enacted, will impose…
To read the full story
Related Article
- Clinical Research Law Promulgated
April 17, 2017
- Clinical Research Bill Passed into Law
April 7, 2017
- Clinical Research Bill Passes Lower House
March 23, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
- Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
June 2, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
REGULATORY
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…